Does pulsatile administration of glucagon-like peptide-1 (GLP-1) when compared to continuous infusion have a greater effect on insulin secretion and blood glucose lowering in healthy humans?
The effects of pulsatile, when compared to continuous, infusion of glucagon-like peptide-1 on insulin secretion and blood glucose in healthy humans
Royal Adelaide Hospital Intensive Care Unit
12 participants
Apr 5, 2013
Interventional
Conditions
Summary
The purpose of this study is to determine the optimum administration method of glucagon-like peptide-1 (GLP-1), by evaluating whether pulsatile administration of GLP-1 causes greater insulin secretion and glucose lowering when compared with continuous administration.
Eligibility
Inclusion Criteria1
- Healthy volunteers able to give informed consent
Exclusion Criteria12
- Inability to give informed consent
- History of diabetes
- Women who are pregnant or lactating
- History of pancreatitis
- Haemoglobin <125g/L for women and <135g/L for men
- Glycated haemoglobin (HbA1c) >6.0 %
- Ferritin levels for women <10microgram/L and <20microgram/L for men
- Estimated glomerular filtration rate < 60ml/min
- Impaired liver function (ALT: >55 U/L; Albumin: <34g/l; ALP: >110 U/L; Bilirubin: >25 micro mol; GGT: >80U/L)
- Blood donation within the previous 12 weeks
- BMI <18.5 or >30kgm^2
- Taking blood-glucose lowering drugs
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intervention: 1ml bolus of glucagon-like peptide-1 (GLP-1)at 3.6 pmol/kg every 6 minutes and a continuous infusion of 0.9% isotonic saline (1 ml/min) both intravenously for 120min. Subjects will be studied on three occasions sperated by a minimum of 3 days.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612001040853